An open-label, randomized phase III trial of gemcitabine and carboplatin (GC) followed by Epstein-Barr virus-specific autologous cytotoxic t lymphocytes (EBV-CTLs) versus GC as front-line therapy for patients (pts) with advanced nasopharyngeal carcinoma (NPC).

Authors

Han Chong Toh

Tessa Therapeutics Pte Ltd, Singapore, Singapore

Han Chong Toh , Josemund Menezes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).

First Author: Shom Goel

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.

First Author: Jin Li

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).

First Author: Markus H. Moehler

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

First Author: Yelena Yuriy Janjigian